Page 13 - Martin Shkreli Case Study

- Roche, the Swiss drugmaker, and Germany’s Merck each fell
more than 2%.

In the UK, the National Health Service is the main buyer and prices are
set through a voluntary scheme between manufacturers and the
government, trying to strike the right balance of serving patients and
generating money to keep the drug pipeline going. Profits are capped to
stop prices creeping too high.

In the US, the buyers are private insurance companies as well as the
government through the Medicare and Medicaid system. It's a market
and prices can go up and down, depending on what people are willing to
pay.

'Would you prefer (1) a lower price of our medicine, which is
overwhelmingly paid for by 'Corporate America' and their insurers (who
are reporting record profits) or (2) that we use our resources to research
a new drug for resistant strains of this neglected disease,'

the text read.

He included a passage of text which claimed that the use of Daraprim

has 'eventually led to the inevitable selection of resistant strains'.

“No less an authority than Donald Trump said that Shkreli “looks
like a spoiled brat.”